Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (March 2023)
27 slides from Trendlines's investor presentation, March 2023
Slide 1: Investing to improve the human condition
Investing to improve the human condition Food and Health Steve Rhodes Todd Dollinger Haim Brosh Chair and CEO Chair and CEO CFO March 2023
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Agenda
Agenda • 2022 selected portfolio achievements • Overview of portfolio + guest presentation by Escala Medical CEO • New portfolio valuation information • FY 2022 financial sum-up • Q&A
Slide 4: We invest in agrifood and medical tech innovation to improve the human condition
We invest in agrifood and medical tech innovation to improve the human condition 15 Years’ investment 56* portfolio 20 advanced-stage 10 exits and company companies companies building experience * including consolidated portfolio companies 9.7X return and 175% IRR on exits Equity US$96 million (31.1
Slide 5: Selected 2022 achievements
Selected 2022 achievements Selected raises Strategic collaborations Regulatory Clinical & field trials Completed to US$19 million FDA clearance US$14.5million US$1.6 million FDA breakthrough device designation US$2.8 million 5
Slide 6: A taste of our portfolio
A taste of our portfolio. “s: trendlines
Slide 7: Some portfolio stats
Some portfolio stats 56* 17 20 8 portfolio revenue-stage companies with consolidated companies companies strategic companies partnerships 23 33 agrifood medtech * including consolidated portfolio companies 7
Slide 8: The natural food color revolution
The natural food color revolution A broad-spectrum of healthy plant-based colors produced via Founded 2018; fermentation technology, using baker’s yeast as a biofactory. 23 employees; Phytolon’s high-quality and cost-effective pigments offer value Yokne’am Illit, IL for consumers, the environment an
Slide 9: 4 more agrifood frontrunners
4 more agrifood frontrunners 23 agrifood portfolio companies Early-stage prediction of Technology platform for Artificial intelligence Orally-administered disease crop yields in orchards harvesting greenhouse analytics employing drones prevention for shrimp and and vines tomatoes for user-generated
Slide 10: Nonsurgical prolapse repair device
Nonsurgical prolapse repair device Minimally invasive, nonsurgical, incision-free and mesh-free repair device to treat pelvic organ prolapse (POP) in the ambulatory or office-based settings. Founded 2014 Achievements CEO Edit Goldberg • Received FDA clearance (April 2022) IP Granted US patent, • Suc
Slide 11: 4 more leading medtech companies
4 more leading medtech companies 33 medtech portfolio companies Meniscus repair system Removable stent following Digital home dialysis A small, game-changing • FDA and CE clearance sinus surgery device to prevent preterm birth. • FDA clearance • Launched initial • FDA clearance • FIH clinical study
Slide 12: Let's look at the numbers
Let’s look at the numbers. “s: trendlines
Slide 13: Portfolio value with cumulative exit proceeds
Portfolio value with cumulative exit proceeds US$ 160 millions 140 Portfolio value (w/o 8 consolidated companies) 120 Cumulative exit proceeds 100 80 60 40 20 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 13
Slide 14: Portfolio cluster values
Portfolio cluster values Non-IFRS Value Fair Value of Trendlines’ Share Cluster of Trendlines’ (additional information) To better evaluate our portfolio, we divided Share (US$'000) (US$'000) it into 12 “clusters,” based on their activities. Aquaculture & Animal Health US$5,038 US$8,376 Here is the t
Slide 15: Book value vs. exit value
Book value vs. exit value US$ millions 60 50 40 30 4.4X is the increase in value 20 of our ten exits, compared to 10 their pre-exit book value. 0 Trendlines’ pre-exit book value Trendlines’ book value at exit 15
Slide 16: Investments raised by portfolio companies
Investments raised by portfolio companies* 45 100,000 US$ million 40 90,000 80,000 35 70,000 30 60,000 25 50,000 20 40,000 15 30,000 10 20,000 5 10,000 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total # of companies that raised Total amount raised *Including ventu
Slide 17: FY 2022: Key Financial Metrics
FY 2022: Key Financial Metrics 31 December 2022 31 December 2021 Portfolio value: US$89.8 million US$83.0 million Total Equity: US$95.9 million US$102.5 million NAV per share: US$0.11 US$0.13 Net (loss)/profit US$ (15.2 million) US$6.0 million 17
Slide 18: Balance sheet (Group)
Balance sheet (Group) Assets (US$’000) (US$’000) Current assets 31 December 2022 31 December 2021 Non-current assets 31 December 2022 31 December 2021 Cash and cash Investments in portfolio 4,565 14,309 89,777 83,046 equivalents companies Short-term bank Accounts and other 2,092 4,252 1,489 5,276 de
Slide 19: Balance sheet (Group)
Balance sheet (Group) Liabilities (US$’000) (US$’000) Current liabilities 31 Dec 2022 31 Dec 2021 Long-Term liabilities 31 Dec 2022 31 Dec 2021 Lease liability 419 776 Deferred revenues 888 679 Loans 292 4,241 Loans from the Israel 2,469 2,718 Trade and other Innovation Authority 3,393 4,246 payable
Slide 20: Consolidated condensed report of income (Group)
Consolidated condensed report of income (Group) Consolidated statements of profit or loss (US$’000) Income 31 Dec 2022 31 Dec 2021 Gain/Loss from change in fair value of investments in portfolio companies (2,470) 9,151 Income from services to portfolio companies 2,556 1,542 Income from contracted R&
Slide 21: Consolidated condensed report of income (Group)
Consolidated condensed report of income (Group) Consolidated statements of profit or loss (US$’000) Expenses 31 Dec 2022 31 Dec 2021 Operating, general and administrative expenses 10,299 9,388 Operating, general and administrative expenses – 1,316 1,737 Trendlines Medical Singapore portfolio compani
Slide 22: Building for future results
Building for future results 22
Slide 23: Medtech portfolio clusters
Medtech portfolio clusters Home Urology & Spine & Cardiology, Neurology Healthcare Women’s Health Orthopedics & Anesthesia IFRS Value: US$6,138 IFRS Value: US$11,142 IFRS Value: US$10,462 IFRS Value: US$4,301 Non-IFRS: US$13,074 Non-IFRS: US$27,506 Non-IFRS: US$14,261 Non-IFRS: US$6,495 AyzerSense |
Slide 24: Agrifood portfolio clusters
Agrifood portfolio clusters Crop Digitization Future Food Protection & Robotics & Ingredients IFRS Value: US$6,439 IFRS Value: US$7,979 IFRS Value: US$10,926 Non-IFRS: US$9,633 Non-IFRS: US$16,294 Non-IFRS: US$18,729 EcoPhage | AgroScout | FruitSpec | AlgaHealth | Celleste | IBI-Ag | ProJini MetoMot
Slide 25: Notes and Disclaimer
Notes and Disclaimer The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at which we carry these investments on our balance sheet, were calculated on the basis of recent portfolio company transactions (last 12 months), as follows: 1. In cases where the last
Slide 26: Investing to improve the human condition
Investing to improve the human condition SGX: 42T Steve Rhodes, Chair and CEO OTCQX: TRNLY steve@trendlines.com +972.72.260.7000 Todd Dollinger, Chair and CEO www.trendlines.com todd@trendlines.com Haim Brosh, CFO March 2023 haim@trendlines.com
Slide 27: General Announcement: Presentation for call March 2023
GENERAL ANNOUNCEMENT::PRESENTATION FOR INVESTOR UPDATE CALL MARCH 2023 Issuer & Securities Issuer/ Manager THE TRENDLINES GROUP LTD. Securities THE TRENDLINES GROUP LTD. - 1L0011328858 - 42T Stapled Security No Announcement Details Announcement Title General Announcement Date &Time of Broadcast 26-M
The Trendlines Group — Investor Presentation (March 2023) on 6ix